Cargando…

The German National Program on Psoriasis Health Care 2005–2015: results and experiences

In 2005, the first national psoriasis survey in Germany revealed large deficits in health care particularly in patients with moderate to severe disease. The consecutive goal was to improve health care for psoriasis countrywide. For this, a large-scale national program was initiated starting with a c...

Descripción completa

Detalles Bibliográficos
Autores principales:	Augustin, M., Eissing, L., Langenbruch, A., Enk, A., Luger, T., Maaßen, D., Mrowietz, U., Reich, K., Reusch, M., Strömer, K., Thaçi , D., von Kiedrowski, R., Radtke, M. A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2016
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4940437/ https://www.ncbi.nlm.nih.gov/pubmed/27048503 http://dx.doi.org/10.1007/s00403-016-1637-8

Ejemplares similares

Drug safety of systemic treatments for psoriasis: results from The German Psoriasis Registry PsoBest
por: Reich, K., et al.
Publicado: (2015)

A 24‐week multicentre, randomized, open‐label, parallel‐group study comparing the efficacy and safety of ixekizumab vs. fumaric acid esters and methotrexate in patients with moderate‐to‐severe plaque psoriasis naive to systemic treatment
por: Reich, K., et al.
Publicado: (2019)

Sex-related impairment and patient needs/benefits in anogenital psoriasis: Difficult-to-communicate topics and their impact on patient-centred care
por: da Silva, Neuza, et al.
Publicado: (2020)

Nail psoriasis as a severity indicator: results from the PsoReal study
por: Radtke, Marc A, et al.
Publicado: (2010)

German evidence-based guidelines for the treatment of Psoriasis vulgaris (short version)
por: Nast, A., et al.
Publicado: (2007)

Secukinumab demonstrates high sustained efficacy and a favourable safety profile in patients with moderate‐to‐severe psoriasis through 5 years of treatment (SCULPTURE Extension Study)
por: Bissonnette, R., et al.
Publicado: (2018)

Network meta‐analysis of biologic treatments for psoriasis using absolute Psoriasis Area and Severity Index values ≤1, 2, 3 or 5 derived from a statistical conversion method
por: Mrowietz, U., et al.
Publicado: (2021)

Management der Psoriasis
por: Mrowietz, Ulrich
Publicado: (2021)

Canine Cutaneous Plasmacytosis: 21 Cases (2005–2015)
por: Boostrom, B.O., et al.
Publicado: (2017)

Qualität der dermatologischen Versorgung von Neurodermitis in Deutschland – keine Verbesserung der Indikatoren nach 10 Jahren
por: Langenbruch, A., et al.
Publicado: (2021)

Continuous dosing versus interrupted therapy with ixekizumab: an integrated analysis of two phase 3 trials in psoriasis
por: Blauvelt, A., et al.
Publicado: (2017)

Switching from a fumaric acid ester mixture to dimethylfumarate monotherapy in psoriasis
por: Warren, R.B., et al.
Publicado: (2019)

Addressing challenges associated with long‐term topical treatment and benefits of proactive management in patients with psoriasis
por: Lebwohl, M., et al.
Publicado: (2021)

Long‐term efficacy of certolizumab pegol for the treatment of plaque psoriasis: 3‐year results from two randomized phase III trials (CIMPASI‐1 and CIMPASI‐2)
por: Gordon, K.B., et al.
Publicado: (2020)

Direct comparison of risankizumab and fumaric acid esters in systemic therapy–naïve patients with moderate‐to‐severe plaque psoriasis: a randomized controlled trial
por: Thaçi, D., et al.
Publicado: (2021)

Behandlung der Psoriasis mit Secukinumab: Praxisrelevante Hinweise
por: Körber, Andreas, et al.
Publicado: (2021)

Leptospirosis in Zakarpattia Oblast (2005–2015)
por: Markovych, Olga, et al.
Publicado: (2019)

National trends in emergency department closures, mergers, and utilization, 2005-2015
por: Venkatesh, Arjun K., et al.
Publicado: (2021)

Incidence, Distribution, and Lethality of Firearm Injuries in California From 2005 to 2015
por: Spitzer, Sarabeth A., et al.
Publicado: (2020)

Treatment Options and Goals for Patients with Generalized Pustular Psoriasis
por: Krueger, James, et al.
Publicado: (2022)

Manifestation of palmoplantar pustulosis during or after infliximab therapy for plaque-type psoriasis: report on five cases
por: Mössner, Rotraut, et al.
Publicado: (2008)

Predictors and burden of injury mortality in the Thai cohort study 2005–2015
por: Lowe, C. T., et al.
Publicado: (2020)

Widening inequalities in multimorbidity? Time trends among the working population between 2005 and 2015 based on German health insurance data
por: Tetzlaff, Juliane, et al.
Publicado: (2018)

Patient references in the 2005 and 2015 CanMEDS frameworks
por: Adam, Holly L, et al.
Publicado: (2023)

Symptom Experience and Content Validity of the Psoriasis Symptom Scale (PSS) in Patients with Generalized Pustular Psoriasis (GPP)
por: Burden, A. David, et al.
Publicado: (2022)

Multiple switches between GP2015, an etanercept biosimilar, with originator product do not impact efficacy, safety and immunogenicity in patients with chronic plaque‐type psoriasis: 30‐week results from the phase 3, confirmatory EGALITY study
por: Gerdes, S., et al.
Publicado: (2017)

Definition of treatment goals for moderate to severe psoriasis: a European consensus
por: Mrowietz, U., et al.
Publicado: (2010)

Spotlight on Topical Long-Term Management of Plaque Psoriasis
por: Carrascosa, Jose Manuel, et al.
Publicado: (2020)

Involuntary hospitalization – German court proceedings 1992–2005
por: Spengler, Andreas
Publicado: (2007)

Psychosocial Distress of Patients with Psoriasis: Protocol for an Assessment of Care Needs and the Development of a Supportive Intervention
por: Zill, Jördis Maria, et al.
Publicado: (2018)

Training and Retaining Physician‒Scientists in Dermatology: The German Perspective
por: Sies, Katharina, et al.
Publicado: (2021)

Dupilumab Treatment of Atopic Dermatitis in Routine Clinical Care: Baseline Characteristics of Patients in the PROLEAD Prospective, Observational Study
por: Thaçi, Diamant, et al.
Publicado: (2022)

Long‐term efficacy and safety of tildrakizumab for moderate‐to‐severe psoriasis: pooled analyses of two randomized phase III clinical trials (reSURFACE 1 and reSURFACE 2) through 148 weeks
por: Reich, K., et al.
Publicado: (2019)

Trends in Psychiatric Hospitalization of Children and Adolescents in Spain between 2005 and 2015
por: Llanes-Álvarez, Carlos, et al.
Publicado: (2019)

Publication characteristics of studies published in The Spine Journal from 2005 to 2015
por: Park, Joseph, et al.
Publicado: (2019)

Safety of Brodalumab in Plaque Psoriasis: Integrated Pooled Data from Five Clinical Trials
por: REICH, Kristian, et al.
Publicado: (2022)

Amputation rates of the lower limb by amputation level – observational study using German national hospital discharge data from 2005 to 2015
por: Spoden, Melissa, et al.
Publicado: (2019)

Epidemiology of Leprosy in Iran from 2005 to 2015
por: Mansori, Kamyar, et al.
Publicado: (2017)

PsoBarrier EU study: a Multicentre, Cross-sectional Survey Investigating the Quality of Psoriasis Care in Four European Countries
por: LANGENBRUCH, Anna, et al.
Publicado: (2023)

The role of the interleukin‐23/Th17 pathway in cardiometabolic comorbidity associated with psoriasis
por: Egeberg, A., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_k7kaqnnm1lf234t3ng1613abl9